Jasper Therapeutics’ (JSPR) “Outperform” Rating Reaffirmed at Royal Bank of Canada

Jasper Therapeutics (NASDAQ:JSPR)‘s stock had its “outperform” rating restated by stock analysts at Royal Bank of Canada in a research report issued on Monday,Benzinga reports. They presently have a $68.00 price target on the stock. Royal Bank of Canada’s price target would indicate a potential upside of 213.22% from the company’s previous close.

A number of other research analysts also recently issued reports on JSPR. JMP Securities reiterated a “market outperform” rating and issued a $70.00 price target on shares of Jasper Therapeutics in a report on Tuesday, October 15th. BMO Capital Markets started coverage on Jasper Therapeutics in a research note on Friday, December 6th. They issued an “outperform” rating and a $63.00 target price on the stock. Cantor Fitzgerald reissued an “overweight” rating on shares of Jasper Therapeutics in a research report on Monday, September 9th. Evercore ISI reaffirmed an “outperform” rating and issued a $65.00 price objective on shares of Jasper Therapeutics in a research report on Monday, August 26th. Finally, HC Wainwright reiterated a “buy” rating and set a $65.00 price objective on shares of Jasper Therapeutics in a research note on Thursday, October 24th. Ten analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock presently has an average rating of “Buy” and an average price target of $73.38.

Jasper Therapeutics Price Performance

Shares of Jasper Therapeutics stock opened at $21.71 on Monday. The stock has a market cap of $325.67 million, a price-to-earnings ratio of -4.58 and a beta of 2.18. The firm’s 50-day moving average is $21.81 and its two-hundred day moving average is $20.65. Jasper Therapeutics has a 1 year low of $5.02 and a 1 year high of $31.01.

Hedge Funds Weigh In On Jasper Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in JSPR. BNP Paribas Financial Markets grew its stake in Jasper Therapeutics by 208.6% during the 3rd quarter. BNP Paribas Financial Markets now owns 2,512 shares of the company’s stock valued at $47,000 after purchasing an additional 1,698 shares during the last quarter. Wolff Wiese Magana LLC acquired a new stake in shares of Jasper Therapeutics during the third quarter worth about $59,000. MetLife Investment Management LLC boosted its position in Jasper Therapeutics by 129.1% in the third quarter. MetLife Investment Management LLC now owns 6,874 shares of the company’s stock valued at $129,000 after buying an additional 3,873 shares during the last quarter. Rhumbline Advisers acquired a new position in Jasper Therapeutics in the 2nd quarter worth approximately $300,000. Finally, Jane Street Group LLC purchased a new position in Jasper Therapeutics during the 3rd quarter worth approximately $251,000. Hedge funds and other institutional investors own 79.85% of the company’s stock.

About Jasper Therapeutics

Jasper Therapeutics, Inc, a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy.